These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37144331)

  • 1. Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?
    Casaluce F; Gridelli C
    Expert Opin Emerg Drugs; 2023 Dec; 28(2):121-127. PubMed ID: 37144331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT).
    Gridelli C; Peters S; Velcheti V; Attili I; de Marinis F
    ESMO Open; 2023 Apr; 8(2):101192. PubMed ID: 36965261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of combination chemo-immunotherapy in advanced non-small cell lung cancer.
    Rocco D; Della Gravara L; Battiloro C; Gridelli C
    Expert Rev Anticancer Ther; 2019 Jul; 19(7):561-568. PubMed ID: 31188040
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
    Su C; Zhou F; Shen J; Zhao J; O'Brien M
    Eur J Cancer; 2017 Sep; 83():266-278. PubMed ID: 28763691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
    Kuon J; Hommertgen A; Krisam J; Lasitschka F; Stenzinger A; Blasi M; Bozorgmehr F; Maenz M; Kieser M; Schneider M; Thomas M
    Trials; 2020 Apr; 21(1):352. PubMed ID: 32321565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?
    Rocco D; Della Gravara L; Franzese N; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):183-189. PubMed ID: 34989305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges associated with systemic therapy for older patients with inoperable non-small cell lung cancer.
    O'Leary C; McSorley L; Hennessy B; Grogan L; Breathnach O; Morris P
    Expert Opin Pharmacother; 2020 Dec; 21(17):2185-2194. PubMed ID: 32866411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Huang J; Reckamp KL
    Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer.
    Gomes F; Tay R; Chiramel J; Califano R
    Drugs Aging; 2018 Sep; 35(9):819-834. PubMed ID: 30105645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung Cancer.
    Rocco D; Della Gravara L; Battiloro C; Gridelli C
    Expert Opin Biol Ther; 2021 Mar; 21(3):303-309. PubMed ID: 33355496
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives.
    Cella E; Zullo L; Marconi S; Rossi G; Coco S; Dellepiane C; Alama A; Rozeboom L; Bennicelli E; Parisi F; Sacco G; Barletta G; Zinoli L; Tagliamento M; Pronzato P; Genova C
    Expert Opin Biol Ther; 2022 Oct; 22(10):1259-1273. PubMed ID: 35994596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.
    Gridelli C; Aapro M; Ardizzoni A; Balducci L; De Marinis F; Kelly K; Le Chevalier T; Manegold C; Perrone F; Rosell R; Shepherd F; De Petris L; Di Maio M; Langer C
    J Clin Oncol; 2005 May; 23(13):3125-37. PubMed ID: 15860872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review.
    Naltet C; Besse B
    Transl Lung Cancer Res; 2021 Jun; 10(6):3014-3028. PubMed ID: 34295694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents.
    Meoni G; Cecere FL; Lucherini E; Di Costanzo F
    J Geriatr Oncol; 2013 Jul; 4(3):282-90. PubMed ID: 24070465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.